Brooklyn ImmunoTherapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported Loss from operations was $10,013,130 against $2,019,201 a year ago. Net loss was 10,085,317 or $0.24 per basic and diluted share against $2,033,446 or $0.12 per basic and diluted share a year ago. For the six months, the company reported Loss from operations was $18,114,727 against $3,033,735 a year ago. Net loss was $27,787,651 or $0.79 per basic and diluted share against $3,052,658 or $0.17 per basic and diluted share a year ago.